DACOMITINIB for Targeted cancer therapy: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where DACOMITINIB was used for Targeted cancer therapy.
Most Reported Side Effects for DACOMITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 253 | 37.1% | 253 | 18 |
| Diarrhoea | 114 | 16.7% | 23 | 36 |
| Rash | 108 | 15.8% | 22 | 17 |
| Neoplasm progression | 78 | 11.4% | 39 | 14 |
| Paronychia | 55 | 8.1% | 5 | 10 |
| Blood pressure increased | 47 | 6.9% | 9 | 7 |
| Off label use | 35 | 5.1% | 10 | 10 |
| Pruritus | 34 | 5.0% | 7 | 9 |
| Dyspnoea | 30 | 4.4% | 7 | 13 |
| Carcinoembryonic antigen increased | 28 | 4.1% | 5 | 2 |
| Pain | 28 | 4.1% | 4 | 7 |
| Decreased appetite | 27 | 4.0% | 13 | 8 |
| Malignant neoplasm progression | 26 | 3.8% | 11 | 6 |
| Vomiting | 26 | 3.8% | 10 | 9 |
| Asthenia | 24 | 3.5% | 6 | 8 |
Other Indications for DACOMITINIB
Non-small cell lung cancer (103)
Lung neoplasm malignant (76)
Lung adenocarcinoma (63)
Lung cancer metastatic (39)
Non-small cell lung cancer metastatic (36)
Lung adenocarcinoma stage iv (12)
Product used for unknown indication (10)
Non-small cell lung cancer stage iv (7)
Adenocarcinoma (6)
Egfr gene mutation (6)
Other Drugs Used for Targeted cancer therapy
OSIMERTINIB (109)
OLAPARIB (44)
REGORAFENIB (33)
TRASTUZUMAB DERUXTECAN (22)
CYCLOPHOSPHAMIDE (19)
TRASTUZUMAB (19)
PEMBROLIZUMAB (18)
TUCATINIB (17)
DABRAFENIB (16)
FAM-TRASTUZUMAB DERUXTECAN-NXKI (16)